Loading company
Orasure Technologies Inc.
OSUR · Nasdaq · Healthcare · Medical Instruments and Supplies
Next earnings: November 4, 2026
$3.81-3.5%Sep 29 close
- 1M
- +5.8%
- 6M
- +30.5%
- 1Y
- +18.7%
- 5Y
- -65.2%
OSUR · Nasdaq · Healthcare · Medical Instruments and Supplies
Next earnings: November 4, 2026
$3.81-3.5%Sep 29 close
Orasure Technologies Inc. is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $30.6M | $31.2M | -1.93% |
| Profit | $6.2M | -$19.7M | +131.73% |
| Profit per share | $0.09 | -$0.26 | +134.62% |
| Free Cash Flow | -$12.3M | -$12.2M | -1.56% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Our Q2 results demonstrate continued progress in our return-to-growth trajectory, with revenue of $30.6 million, up 9.7% sequentially and above our guidance range, along with solid gross margin improvement,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
OraSure Technologies, Inc. (“OraSure” and “OTI”) transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. Together with its wholly-owned subsidiaries, DNA Genotek Inc., Sherlock Biosciences, Inc., and BioMedomics, Inc., OTI is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physicians’ offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Orasure Technologies Inc.’s Item 2.02 8-K filed August 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Orasure Technologies Inc. has no earnings call transcript available.